RNVA

-- -- --

Rennova Health, Inc. announced that the Company will effect a 1 for 15 reverse stock split on The NASDAQ Capital Market on Friday October 6, 2017, on a post-split basis.The reverse stock split will reduce the number of shares of the Company’s common stock outstanding from approximately 20.4 million pre-reverse split shares to approximately 1.4 million post-reverse split.

On July 17, 2017, the Company closed an offering of $4,136,862 aggregate principal amount of Original Issue Discount Debentures due October 17, 2017 and warrants to purchase an aggregate of 2,120,000 shares of common stock for consideration of $2,000,000 in cash and the exchange of the $1,902,700 aggregate principal amount of Original Issue Discount Debentures due September 22, 2017 issued by the Company on June 22, 2017.

From December 31, 2016 to June 30, 2017 Conversion of preferred stock into common stock Exchange of preferred stock for convertible debentures Common stock issued in exchange for warrants Shares issued in settlement of notes payable Conversion of debentures into common stock Rounding up of common shares in connection with reverse stock split Common stock granted to employees

from December 31, 2016 to March 31, 2017 Conversion of preferred stock into common stock Common stock issued in exchange for warrants Shares issued in settlement of notes payable Exchange of preferred stock for convertible debentures Conversion of debentures into common stock Rounding up of common shares in connection with reverse stock split Common stock granted to employees

On February 7, 2017, Rennova Health, Inc. today announced that effective at 5:00 pm, Eastern Time, on February 22, 2017 (the “Effective Time”), the Company will effect a 1 for 30 reverse stock split of its outstanding common stock. The Company’s common stock will open for trading on The NASDAQ Capital Market on February 23, 2017 on a post-split basis.

As previously announced, the Company closed on an offering of preferred stock on December 20, 2016. The Company currently has 84,011,068 shares of common stock outstanding.

from December 31, 2015 to December 31, 2016 Conversion of Series C Preferred shares into common stock Exchange of Series C Preferred Stock and warrants for Series G Preferred Stock and warrants Conversion of Series G Preferred Stock into common stock Conversion of Series B Preferred shares into common stock Cancellation of Series E Preferred Stock Issuance of Series H Preferred Stock for cash Redemption of Series G Preferred Stock Conversion of Series H Preferred Stock into common stock Cashless exercise of warrants Shares issued in adjustment of prior conversion of preferred stock Common shares cancelled Issuance of shares for services Common stock and warrants issued for cash Conversion of related party liabilities into common stock Common stock granted to employees

from December 31, 2015 to September 30, 2016 Conversion of preferred stock into common stock Exchange of Series C Preferred Stock and warrants for Series G Preferred Stock and warrants Cancellation of Series E Preferred Stock Common stock and warrants issued for cash Conversion of related party liabilities into common stock Common stock granted to employees

The issuance of the shares of common stock and warrants was exempt from the registration requirements of the Securities Act of 1933, as amended, in accordance with Section 4(a)(2) thereof, as a transaction by an issuer not involving any public offering.

From December 31, 2015 to June 30, 2016 Conversion of Series C Preferred shares into common stock Cashless exercise of warrants Shares issued in adjustment of prior conversion of preferred stock Common shares cancelled Issuance of shares for services

From November 2, 2015 to December 31, 2015 Cancellation of Medytox shares Issuance of Rennova shares Stock issued for cash, net of offering costs of $1,156,663 Shares issued in merger with CollabRx, Inc. On November 2, 2015, the Company completed its merger. Prior to closing, the Company amended its certificate of incorporation to effect a 1-for-10 reverse stock split.

On November 2, 2015, pursuant to the terms of the Agreement and Plan of Merger, dated as of April 15, 2015, by and among CollabRx, Inc. (“CollabRx”), CollabRx Merger Sub, Inc. (“Merger Sub”), a direct wholly owned subsidiary of CollabRx formed for the purpose of the merger, and Medytox Solutions, Inc. (“Medytox”), Merger Sub merged with and into Medytox, with Medytox as the surviving company and a direct, wholly-owned subsidiary of CollabRx (the “Merger”). Prior to closing, the Company amended its certificate of incorporation to effect a 1-for-10 reverse stock split and to change its name to Rennova Health, Inc. In connection with the Merger, (i) each share of common stock of Medytox was converted into the right to receive 0.4096377408003329 shares of common stock of the Company, (ii) each share of Series B Preferred Stock of Medytox was converted into the right to receive one share of a newly-authorized Series B Convertible Preferred Stock of the Company, and (iii) each share of Series E Convertible Preferred Stock of Medytox was converted into the right to receive one share of a newly-authorized Series E Convertible Preferred Stock of the Company.

The weighted-average number of shares and the (loss) income per share reflect a 1-for-5 reverse stock split effected by the Company on June 15, 2011.

from March 31, 2014 to March 31, 2015 Proceeds from at-the-market facility Common stock issued Proceeds from exercised warrants Stock compensation expense and released RSU shares In addition to the offering of a total of 7,132,535 shares of common stock through its recent S-1 and S-3 filings, shareholders were offered 4,416,000 warrants to purchase shares of common stock in connection with the February 25, 2015 offering.

from March 31, 2013 to March 31, 2014 Stock issued in connection with 2014 ATM Plan Stock options exercised Stock compensation expense and released restricted stock units

from March 31, 2012 to March 31, 2013 Stock issued for asset acquisition - CollabRx Stock compensation expense and released restricted stock units

from March 31, 2011 to October 18,2011 Common stock repurchases

from March 31 2010 to March 31 2011 Common stock issued stock purchase plans Restricted stock units – vested

From March 31, 2008 to March 31, 2009 Common stock issued stock purchase plans Restricted Stock Units - Vested Stock issued for asset purchase

From March 31, 2007 to March 31, 2008 Common stock issued stock purchase plans Warrants and options to purchase common stock issued for services rendered Restricted stock units – vested

From March 31, 2006 to March 31, 2007 The number of shares outstanding reflects a 1-for-12 reverse stock split effected by the Registrant on July 25, 2006. Common stock issued under option and stock purchase plans Repurchase of fractural shares Restricted stock units - distributed

From March 31, 2005 to March 31, 2006 Common stock issued under option and stock purchase plans Common stock issued for acquisition Debentures – converted to shares Debentures – interest converted to shares Debentures – investor & advisor warrants exercised Private Institutional Offering December 2001 –warrants exercised Kingsbridge

From March 31, 2004 to March 31, 2005 Common stock issued under option and stock purchase plans Common stock issued for acquisition Debentures - converted to shares Debentures - interest converted to shares Debentures - investor & advisor warrants exercised Private Institutional Offering December 2001 - warrants exercised Kingsbridge

From March 31, 2003 to March 31, 2004 Common stock issued under option and stock purchase plans Common stock issued for acquisition Restricted stock issued for services rendered Options and warrants, issued in previous years, exercised for services rendered Debentures - converted to shares Debentures - interest converted to shares Debentures - investor warrants exercised Debentures - broker warrants exercised Private Institutional Offering December 2001 - warrants exercised

From March 31, 2002 to March 31, 2003 Common stock issued under option and stock purchase plans Common stock issued for acquisition Common stock issued for services rendered

From March 31, 2001 to March 31, 2002 Common stock issued under option and stock purchase plans Common stock sold

From March 31, 2000 to March 31, 2001 Common stock issued under option and stock purchase plans

From March 31, 1999 to March 31, 2000 Common stock sold, net of issuance costs of $480 Common stock issued under option and stock purchase plans

From March 31, 1998 to March 31, 1999 Common stock issued under option and stock purchase plans

From March 31, 1997 to March 31, 1998 Common stock issued under option and stock purchase plans

From March 31, 1996 to March 31, 1997 Common stock issued under option and stock purchase plans

From March 31, 1995 to March 31, 1996 Common stock issued under option and executive plans Net proceeds from IPO Conversion of redeemable preferred stock to common stock at IPO